Порталак

Quick links

Choose a section

Quick links to important sections

Advertisements

Порталак

Selected form

Advertisements
Advertisements

Treatment option: Constipation

Advertisements

Overview of Порталак

Quick Facts Overview

Property Description
Active ingredient Lactulose (INN)
Form Oral Solution (Syrup)
Pharmacological class Osmotic Laxative
Common purpose Promoting bowel regularity & assisting ammonia removal
Origin Synthetic Disaccharide

What Type of Medicine is Порталак and What is it Made Of?

Порталак (Portalac) is a trademarked pharmaceutical product whose single active substance is Lactulose (INN), placing it in the pharmacological class of Osmotic Laxatives.

This medication is an oral solution (syrup) designed for ingestion by mouth. Lactulose is formally classified as a synthetic disaccharide, meaning it is a sugar molecule chemically derived from the milk sugar lactose. Lactulose is not easily absorbed into the bloodstream, meaning it works primarily within the digestive tract. This non-absorbable property is key, as it allows the medicine to exert its therapeutic effect directly in the colon and is clinically recognized for its high safety profile in long-term use.

How Does its Primary Action Benefit the Body?

The general purpose of Порталак is to promote comfortable, physiological, and regular bowel movements, as well as to assist in removing excess ammonia from the body.

Lactulose achieves this primarily by acting locally in the large intestine. It works by the osmotic principle, drawing water directly into the colon. This influx of water naturally softens the stool and increases its volume, which encourages the necessary bowel movement. Additionally, lactulose is used for reducing elevated ammonia levels in the blood. This means the medicine offers a dual benefit: it regulates stool consistency and helps the body excrete a potentially toxic substance. This dual capability makes it an important tool for addressing common issues like occasional constipation or for more specialized clinical requirements.

Advertisements

What side effects are possible with Порталак?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient, Lactulose, is structured by classifying possible adverse reactions based on their observed frequency and the organ system affected.


Frequency-Classified Adverse Reactions

The most commonly reported effects involve the gastrointestinal system. According to regulatory classifications, Diarrhoea is the only effect designated as Very Common (ge 1/10). Effects classified as Common (ge 1/100 to <1/10) include Flatulence, Abdominal pain, Nausea, and Vomiting.

Flatulence may appear during the initial few days of treatment but is typically transient. Electrolyte imbalance (e.g., low potassium) is classified as Uncommon and is primarily linked to severe diarrhoea resulting from high-dose or prolonged use.


Serious Safety Considerations

The most significant safety concern documented in regulatory labeling is the potential for severe diarrhoea to lead to serious fluid loss and electrolyte imbalance (such as hypokalaemia or hypernatraemia). This risk is predominantly associated with the high-dose regimen used for specialized conditions like hepatic encephalopathy, where periodic serum electrolyte determinations are considered advisable.


Population-Specific Constraints

The medicine is officially contraindicated in patients diagnosed with Galactosaemia. Caution is also required for diabetic patients due to the presence of small amounts of unabsorbed sugars (lactose/galactose) and for patients who are prone to developing electrolyte disorders if diarrhoea occurs.

Advertisements

Overdose and Emergency Response

The official overdose profile for the active ingredient Lactulose is defined by the consequences of excessive dosage which acts primarily on the gastrointestinal system. Documented clinical signs include the expected major symptoms of persistent diarrhea and severe abdominal cramps; abdominal pain, nausea, and vomiting have additionally been reported in regulatory information.

The primary risk associated with severe overdosage is fluid loss and a resultant disturbance of the electrolyte balance. Prescribing information explicitly states that complications such as hypokalemia (low serum potassium) and hypernatremia (high serum sodium) are potential outcomes. A specific regulatory note indicates that infants may be susceptible to dehydration and hyponatremia resulting from diarrhea.

The mandated first-line intervention for overdosage is the cessation of treatment or an immediate dose reduction. Patients should seek emergency medical attention if overdosage is suspected, particularly when fluid loss appears severe enough to require correction of electrolyte disturbances. No specific antidote is documented for this product, and management consists of symptomatic and supportive care, concentrating on the restoration of fluid and electrolyte balance.

Advertisements

Therapeutic Uses of Порталак

What Порталак (Lactulose) Treats: Main Uses and Benefits

The therapeutic domain for Portalac, which contains the active ingredient lactulose, focuses on the management of specific conditions affecting digestive and systemic comfort. This medication is commonly used to help with symptoms related to constipation and is applied in addressing hepatic encephalopathy (HE).

Lactulose is relevant for easing the overall symptom burden in conditions presenting with physical discomfort and systemic imbalance. It provides supportive relief when symptoms interfere with routine activities. The primary conditions for which it is commonly used to help with are chronic or habitual constipation and the management of hepatic encephalopathy, including its acute episodes and chronic manifestations. The medication may assist with maintaining functional stability during periods of heightened symptoms.

This product is considered relevant for easing symptom clusters that interfere with daily comfort, particularly in clinical scenarios marked by temporary physiological imbalance. The approach is commonly used to help with symptoms related to chronic constipation.

Quick Fact: Relief for Constipation and Systemic Imbalance

The approach supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Порталак (Lactulose)

Official regulatory information defines the eligible populations and strict contraindications for using Lactulose, the active ingredient in Порталак.

Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated in patients with the following conditions, as stated in regulatory labels:

Condition
Galactosaemia (due to trace sugars)
Gastrointestinal Obstruction or subocclusive syndromes
Digestive Perforation or risk of perforation (e.g., acute IBD)
Hypersensitivity to Lactulose or excipients
Painful Abdominal Syndromes of undetermined cause

Age-Specific Eligibility and Restrictions

Age Group Eligibility Status
Adults and Adolescents Generally approved for constipation and hepatic encephalopathy (HE).
Children (0–18 years) Use for constipation is indicated but must be under medical supervision; use for HE is not established (insufficient data).
Infants (under 1 year) Use of laxatives is categorized as exceptional and under medical supervision.

Conditional Use and Special Populations

Lactulose may be used by pregnant and breastfeeding women, as official labeling anticipates no effects due to negligible systemic absorption. Use is restricted to caution for patients with Diabetes Mellitus or those with Lactose/Galactose/Fructose Intolerance. No special eligibility restrictions are stated for patients with mild to moderate renal or hepatic insufficiency.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Порталак (Lactulose) is characterized by pharmacodynamic effects that primarily involve the gastrointestinal environment and electrolyte balance, a pattern consistent with its minimal systemic absorption.

Official Interaction Statements

Category Interacting Substances/Effects
Reduced Therapeutic Effect Co-administration with Oral Anti-infective Agents (e.g., Neomycin) or Nonabsorbable Antacids may inhibit the therapeutic action of Lactulose. The use of antacids may require timing separation to preserve the desired drop in colonic pH.
Increased Toxicity Risk Lactulose-induced fluid loss can potentiate the loss of potassium (Hypokalemia) caused by co-administered Thiazides, Corticosteroids, and Amphotericin B. This hypokalemia subsequently enhances the toxicity of Cardiac Glycosides (e.g., Digoxin).
Additive Effects Concurrent use with other laxatives may result in an additive effect, increasing the risk of adverse effects, specifically loose stools and diarrhea.

Population-Specific Regulatory Note

For elderly and debilitated patients receiving long-term treatment (over six months), regulatory documents state that periodic measurement of serum electrolytes (potassium, chloride, carbon dioxide) is required due to the risk of significant imbalance from sustained diarrhea.

Advertisements

Mechanism of Action

Modulation of Colonic Fluid and Peristalsis

The primary mechanism begins as the unabsorbed lactulose is fermented by the colonic microbiota (saccharolytic bacteria), yielding low molecular weight organic acids. These acids are highly osmotically active, which physically draws water into the intestinal lumen, increasing the bulk and hydration of the stool. This volume expansion provides the necessary physical stimulus to colonic wall contraction (peristalsis).


Chemical Control of Nitrogenous Waste

The second crucial mechanistic domain leverages the same fermentation process. The resulting organic acids dramatically lower the pH of the colonic contents. This acidic environment initiates ion trapping, chemically converting the easily absorbed nitrogenous compound, ammonia ( NH3), into its non-absorbable form, ammonium ( NH4^+) ion. This alteration ensures the trapped NH4^+ is excreted via feces, limiting the amount of NH3 available for transport into the portal blood.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Порталак — Administration Guidelines

This map consolidates the instructions for the use of Порталак (Lactulose oral solution).


Administration Scope

Feature Instruction
Route of administration Primarily Oral solution. The Rectal route is specified for acute hepatic encephalopathy (HE) coma as a retention enema when oral intake is contraindicated.
Dosing schedule Constipation (Adults): Initial dose is 15 mL to 30 mL once daily, which may be increased to 60 mL daily if necessary. HE Maintenance: 30 mL to 45 mL three to four times daily.
Timing in relation to meals The solution may be taken with or without food. For once-daily dosing, it is recommended to be taken at the same time each day.
Preparation requirements The oral solution can be taken undiluted or mixed with water, fruit juice, or milk. Rectal administration requires diluting 300 mL of solution with 700 mL of water or saline.
Age-group administration rules Use in children and infants should be exceptional and administered under medical supervision. No specific dose adjustments are typically required for older adults.
Special procedural conditions Adequate fluid intake (1.5–2 liters per day) is recommended during therapy. Oral therapy must be initiated before rectal enema therapy is stopped entirely for HE management.

Instruction Classifications (High-level)

Classification Pattern
Administration method type Oral solution and Rectal retention enema.
Frequency pattern Once Daily (Constipation) or Multiple Times Daily (HE), requiring titration every 1–2 days.
Use-context constraints Dosage is response-driven; HE dosing is constrained by the goal of achieving 2 to 3 soft stools daily.

Connection to the overall use protocol

The use protocol for Порталак is defined by two distinctly different dosing structures corresponding to the target condition and the administration route. This protocol is response-driven, mandating that the dose and frequency are actively adjusted based on the patient's physiological outcome, such as aiming for a specified frequency of soft stools. The guidelines establish specific preparation instructions and a required transition rule for combining oral and rectal administration during acute episodes of hepatic encephalopathy.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Порталак (Lactulose)

The research related to Порталак (Lactulose) is built upon clinical studies that explore its defined applications in the management of two primary conditions. This overview summarizes the structure of the evidence, the types of patient groups studied, and areas where more research is needed, based on authoritative scientific sources.

Evidence for Use in Managing Chronic Constipation

Research related to this use includes multiple Randomized Controlled Trials (RCTs), comparative studies, and scientific papers that consolidate findings, known as meta-analyses. Studies explored the observed response in populations of adults and certain groups of children experiencing chronic constipation. Research examined endpoints related to changes in physiological function and patient-reported outcomes describing perceived discomfort.

Trial reports noted that measurements of bowel movement frequency described a pattern of increase in the observed populations compared to controls. Research also explored how the measurement of stool consistency evolved in the observed populations.

What Remains Uncertain: The available research primarily consists of studies where follow-up durations were limited, meaning long-term effects are not fully established beyond the initial assessment period of several weeks. Data for certain groups, particularly those with complex or specific comorbid conditions (other than those specifically studied), remain insufficient.


Evidence for Use in Managing Hepatic Encephalopathy (HE)

Research related to the specialized application in managing Hepatic Encephalopathy (HE), which involves systemic imbalance, includes multiple Randomized Controlled Trials and scientific reviews. These studies evaluated the medicine’s application for both addressing acute neurological changes and for preventing the condition from recurring in populations of adults with liver cirrhosis.

What Researchers Studied: The research focused on measuring outcomes related to neurological status and monitoring specific biomarkers, such as the concentration of ammonia in the blood. Prevention trials were designed to observe patients over long durations to track the frequency of symptom recurrence.

What Remains Uncertain: A number of trials included in the broader systematic reviews are older trials, and their methodologies may not align with current standardization, leading to uncertainty in some comparative aspects. Long-term effects are not fully established and comparative evidence is lacking for some alternative approaches.

Key Studies & References Lactulose Oral Solution - MedlinePlus Drug Information

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Порталак (FAQ)


Q: Действие Порталака постепенное или быстрое? (Is the effect of Portalac gradual or fast?)

According to official product information, the action of Portalac is not immediate. The therapeutic effect only occurs after the active substance, Lactulose, reaches the large intestine and is metabolized by the gut bacteria. Therefore, official sources indicate that it typically takes anywhere from 24 to 48 hours to achieve the desired effect.


Q: Что делать, если пропустил прием Порталака? (What should be done if a dose of Portalac is missed?)

General regulatory guidance for a missed dose describes the process as skipping the forgotten dose and continuing with the next scheduled time. Official instructions typically state that a double dose should not be taken to compensate for a missed dose.


Q: Можно ли принимать Порталак при диабете? (Can Portalac be taken with diabetes?)

Official regulatory documents define the required usage condition as requiring caution for patients with Diabetes Mellitus. This caution is due to the presence of small, unabsorbed amounts of certain sugars, such as lactose and galactose, that are formed during the manufacturing process.


Q: Что будет, если выпить слишком много Порталака? (What happens if too much Portalac is taken?)

The most common symptoms expected from taking a dose higher than recommended include diarrhea and abdominal pain. Taking a significantly excessive dose may lead to severe diarrhea, potentially resulting in dehydration and an imbalance of electrolytes (minerals in the blood). Such significant loss of fluid and minerals is described as a risk that necessitates medical evaluation.


Q: Правда ли, что Порталак меняет микрофлору кишечника? (Is it true that Portalac changes the gut microflora?)

The mechanism of action for Portalac is based on its interaction with the intestinal bacteria (microbiota) in the colon. The bacteria break down the medication, producing organic acids. Therefore, its therapeutic effect is dependent on and results from the activity of the colon’s microflora.


Q: Какой вкус у Порталака? (What does Portalac taste like?)

Portalac is an oral solution (syrup), and official product descriptions note that it has a sweet taste.


Q: Можно ли Порталак детям? (Can Portalac be given to children?)

Official regulatory documents state that the use of laxatives, including Portalac, in infants and children is considered exceptional. Administration in these age groups is to be performed under medical supervision.


Q: Влияет ли Порталак на давление или сердце? (Does Portalac affect blood pressure or the heart?)

Direct effects on blood pressure or heart function are not listed as primary effects. However, official information notes that the fluid loss caused by severe diarrhea (a side effect) can potentially increase potassium loss. This hypokalemia (low potassium) can, in turn, increase the toxicity of certain heart medications, such as cardiac glycosides.


Q: Может ли Порталак вызвать аллергию? (Can Portalac cause an allergy?)

Hypersensitivity (an allergic reaction) to lactulose or its excipients (non-active ingredients) is listed as a contraindication in official documents. Although rare, allergic reactions are listed among the possible adverse effects of the medicine.


Q: Снижает ли Порталак эффективность противозачаточных таблеток? (Does Portalac reduce the effectiveness of contraceptive pills?)

There is no direct warning in official interaction documents stating that Portalac reduces the effectiveness of contraceptive pills. However, if the medication causes severe diarrhea or vomiting, as with other oral medications, it could potentially affect the absorption of oral contraceptives.


Q: Можно ли пить алкоголь во время приема Порталака? (Can alcohol be consumed while taking Portalac?)

Official regulatory documents do not contain a direct prohibition on consuming alcohol while taking this medicine. However, alcohol consumption may worsen some side effects of laxatives (e.g., dehydration) or potentially affect the digestive system, which could impact the medicine's effectiveness.


Q: Порталак используется только при запорах? (Is Portalac used only for constipation?)

No, Portalac is officially used for two main indications. In addition to treating chronic constipation, the medicine is also used for the treatment and prevention of hepatic encephalopathy (HE), which is a serious condition related to severe liver disease.


Q: Можно ли его принимать, если есть хронические болезни ЖКТ? (Can it be taken if one has chronic GI diseases?)

Official information explicitly states that Portalac is contraindicated in patients with certain acute gastrointestinal conditions. These include gastrointestinal obstruction, perforation (or risk of perforation), or abdominal pain syndromes of undetermined cause.


Q: Может ли Порталак влиять на аппетит? (Can Portalac affect appetite?)

While not listed as a direct effect on appetite, official documents note that frequent side effects include nausea and vomiting, as well as bloating (flatulence) and abdominal pain. These effects may indirectly influence one's desire to eat.


Q: Можно ли принимать Порталак, если планируешь операцию? (Can Portalac be taken if surgery is planned?)

Official warnings exist for patients who may undergo certain procedures, such as electrocautery during colonoscopy. Since the medication can lead to the accumulation of flammable hydrogen gas in the colon, a special preparation of the bowel may be required before such procedures.


Q: Порталак вызывает обезвоживание? (Does Portalac cause dehydration?)

Portalac works by drawing water into the intestine. However, official safety documentation warns that severe diarrhea, which can result from high doses or misuse, can lead to significant fluid loss. This loss may potentially cause dehydration and electrolyte imbalance. Official instructions include the recommendation for adequate fluid intake during therapy.


Q: Нужно ли менять диету при приеме Порталака? (Is it necessary to change diet while taking Portalac?)

The main dietary instruction found in official guidelines is the recommendation to maintain adequate fluid intake throughout the therapy. Specifically, official instructions recommend consuming 1.5–2 liters of fluid per day while taking Portalac.


Q: Можно ли давать Порталак младенцам? (Can Portalac be given to infants?)

The use of laxatives, including Portalac, in infants (under 1 year of age) is strictly classified in official documents as exceptional. Administration to this group is to be carried out under strict medical supervision.


Q: Есть ли безлактозная версия Порталака? (Is there a lactose-free version of Portalac?)

Portalac is a synthetic disaccharide (Lactulose) chemically derived from the milk sugar lactose. Although the product itself is the main ingredient, it contains trace amounts of lactose, galactose, and other sugars due to its manufacturing process, and therefore cannot be classified as fully lactose-free.


Q: Как определить подделку Порталака? (How to identify counterfeit Portalac?)

Official storage instructions provide a stability check, advising that the solution must not be used if it becomes extremely darkened or cloudy (turbid), as this indicates instability. If these changes are observed, regulatory guidance suggests the product should not be used.


Q: Влияет ли Порталак на усвоение витаминов и минералов? (Does Portalac affect the absorption of vitamins and minerals?)

Official warnings emphasize that prolonged treatment with high doses that cause diarrhea can lead to an imbalance of essential minerals, specifically electrolytes like potassium and chloride. Information regarding the influence on general vitamin or mineral absorption during standard use is not typically covered in the official safety profile.


Q: Как долго можно непрерывно принимать Порталак? (How long can Portalac be taken continuously?)

Official regulatory documents indicate that for prolonged treatment lasting more than six months, particularly in elderly or weakened patients, periodic monitoring of serum electrolyte levels is required. The requirement for monitoring indicates that long-term use, exceeding six months, is a possibility described in the documentation.


Q: Порталак вызывает привыкание, если принимать его долго? (Does Portalac cause dependence if taken long-term?)

Portalac is classified as an osmotic laxative and is not absorbed into the bloodstream. Official regulatory documents do not describe a risk of chemical or physical dependence or addiction in the context of controlled substances.


Q: Почему иногда нужно время, чтобы почувствовать эффект от Порталака? (Why does it sometimes take time to feel the effect of Portalac?)

The medicine must travel to the large intestine, where it is broken down by bacteria. This process of passage and subsequent bacterial fermentation takes time. This biological pathway is why the therapeutic effect is delayed, generally taking between 24 to 48 hours.


Q: Почему в инструкции указаны разные схемы приема? (Why are different dosage schedules specified in the instructions?)

Different dosage schedules are officially mandated because Portalac is used to treat two distinct conditions. Chronic constipation requires a regular dose, while hepatic encephalopathy (HE) requires a different, often higher, dose to actively control blood ammonia levels.

Advertisements

How should Порталак be stored and disposed of?

How to Store and Dispose of Порталак (Lactulose Solution)

Storage and disposal must strictly adhere to regulatory guidelines to maintain product stability and safety.

Storage and Environmental Control

The oral solution must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). The product must be actively protected from freezing and direct light. Freezing may cause the solution to become highly viscous, a change that is reversible upon warming. If the solution becomes extremely darkened or cloudy (turbid), it indicates instability and must not be used.

Container and Disposal

The medicine requires storage in a tight, light-resistant container equipped with a child-resistant closure. It must be kept out of the sight and reach of children at all times.

Expired or unused portions of the medicine should not be flushed down a toilet or poured down a drain; patients must consult a pharmacist or healthcare professional for proper disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Порталак found in:

A-Z Index: